Lymphatic Health

Lymphatic Health: A Comprehensive Reference

1. Definition and Overview

The lymphatic vascular system has an important role in the regulation of tissue pressure, immune surveillance, and the absorption of dietary fat in the intestine. In the context of nutrition and natural health, the term "lymphatic health" encompasses the structural and functional integrity of this system — from the microscopic lymph capillaries that permeate nearly every tissue to the large lymphatic trunks and nodes that filter lymph before returning it to the bloodstream. Impairment of any component of this network has consequences that reach well beyond local swelling, touching metabolic regulation, immune competence, intestinal function, and even neurological maintenance.

The lymphatic vascular system is a one-direction network of thin-walled capillaries and larger vessels covered by a continuous layer of endothelial cells that provides a unidirectional conduit to return filtered arterial and tissue metabolites towards the venous circulation. Their principal function is to maintain fluid homeostasis by removing the protein-rich lymph from the extracellular space among tissues and returning it to the bloodstream.

Under physiological conditions, there is an equilibrium between the fluid filtered through the blood vessel walls into the interstitium (lymphatic load) and its removal by the lymphatic vessel system (transport capacity of the lymphatic drainage system). When this equilibrium is disrupted — whether by structural damage, inflammation, or functional impairment — fluid and protein accumulate in the interstitial tissues, a condition known as lymphedema.

2. Anatomy and Body Systems Involved

2.1 Core Structural Components

Lymphedema is a physically and mentally stressful, chronically progressive disease affecting the interstitium, and based on primary (genetic) or secondary (acquired) damage to the lymphatic drainage system, i.e., the initial lymph vessels (lymph capillaries, lymph sinuses), precollectors, lymph collectors, lymphatic trunks and/or lymph nodes.

The ducts of the lymphatic system interconnect the lymph organs including the bone marrow, lymph nodes, spleen, and thymus gland. Lymph within the ducts transports lymphocyte immune cells such as B-lymphocytes (B-cells) and T-lymphocytes (T-cells) that originate from precursor cells in the bone marrow. From there, B-cells mature in the bone marrow while T-cells mature in the thymus gland after having moved through lymphatic ducts.

2.2 Lymph Node Filtration

Resident macrophages and specialized lymphatic sinus structures play a critical role in filtering lymph-borne substances. The stepwise filtration process orchestrated by lymph nodes prevents the entry of foreign substances into the bloodstream.

2.3 The Intestinal Lymphatic System and Dietary Fat

The lymphatic system in the intestines mainly functions to provide homeostasis in the GI tract by filtering fluids, blood cells, and plasma proteins that enter the tissue from the blood. Its role in lipid transport is of special nutritional relevance: water-soluble substances such as amino acids, glucose, and short-chain fatty acids are transferred to the portal vein through blood capillaries, while lipophilic substances associated with chylomicrons enter lymphatics.

Following digestion in the intestinal lumen, absorption, and re-esterification of fatty acids and monoacylglycerols in intestinal enterocytes, triglycerides are packaged into lipoprotein particles (chylomicrons) for secretion or into cytoplasmic lipid droplets for transient or more prolonged storage.

2.4 The Central Nervous System: The Glymphatic and Meningeal Lymphatic Systems

A major frontier in lymphatic biology is the discovery of functionally significant lymphatic structures in the brain. Meningeal lymphatic vessels and the glymphatic system play roles in maintaining fluid balance, clearance of neurotoxic proteins, and immune surveillance in the brain. The glymphatic system, a brain-wide waste clearance network mediated by cerebrospinal fluid–interstitial fluid exchange, is critical in Alzheimer's disease (AD) pathogenesis. Glymphatic dysfunction promotes amyloid-β (Aβ) and tau accumulation, neuroinflammation, and vascular impairment, forming a vicious cycle that drives neurodegeneration.

Recent discoveries about the brain lymphatic drainage system have precipitated a growing body of investigations substantiating its novel roles, including the clearance of macromolecular waste and the trafficking of immune cells. Notably, aquaporin 4-mediated glymphatic transport, crucial for maintaining neural homeostasis, becomes disrupted during aging.

2.5 Multi-System Involvement of Lymphatic Dysfunction

Lymphatic vascular defects have been revealed in inflammatory diseases, Crohn's disease, obesity, cardiovascular disease, hypertension, atherosclerosis, and Alzheimer's disease. This broad disease involvement underscores why lymphatic health is increasingly recognized as a systemic concern rather than a problem confined to isolated regions of swelling.

3. Clinical Presentation: Lymphedema and Related Conditions

3.1 Lymphedema Defined

Lymphedema is a chronic, progressive condition caused by impaired lymphatic drainage, leading to the abnormal accumulation of protein-rich lymphatic fluid in the interstitial tissues. When lymphatic transport capacity is exceeded, persistent edema triggers inflammation and progressive tissue remodeling, resulting in functional decline.

Lymphedema is defined as a localized accumulation of protein-rich interstitial fluid that is otherwise normally drained through the lymphatic system, resulting in the swelling of the affected tissue. Most cases of lymphedema affect the upper or lower extremities, but any body part can be involved.

3.2 Classification: Primary vs. Secondary

Lymphedema is classified as primary when caused by a genetic predisposition (inherited or congenital) directly affecting any part of the lymphatic vascular system, or, much more often, as secondary (acquired) when caused by factors outside the lymphatic system, such as tumours or their treatment.

3.3 Staging

In accordance with the International Society of Lymphology, lymphedema is classified into three stages (I, II, III) and a subclinical stage, in which malfunctioning or damage to the lymph vessels is present but has not yet manifested clinically. Lymphedema is a condition that, in stages I and II, causes an accumulation of fluid in the interstitium, which is initially free and later becomes bound to ground substance (glycosaminoglycans).

3.4 Epidemiology

Lymphedema is a disabling condition that is both underdiagnosed and undertreated. Lymphedema was present in 0.45% of all hospitalizations in the United States, with prevalence increasing from 0.40% in 2016 to 0.50% in 2020. The in-hospital fatality rate was 2.3%, the median length of stay was 5 days, and each hospitalization incurred a median of $36,304 — roughly three times higher than average hospitalization costs in the same period. These findings highlight that lymphedema, although underdiagnosed, affects a significant number of patients and is associated with a considerable burden of both comorbidities and costs.

4. Contributing and Associated Factors

4.1 Cancer Treatment as a Secondary Cause

Lymphedema is a common complication of cancer treatment that results in the accumulation of protein-rich interstitial fluid, fibrosis, and adipose deposition. Epidemiological studies have identified a number of predisposing conditions for developing lymphedema, including obesity, radiation therapy, and postoperative infections.

4.2 Obesity

Obesity is one of the most extensively studied modifiable factors in lymphatic dysfunction. Recent studies have shown that obesity can markedly impair lymphatic function. Obesity-induced pathologic changes in the lymphatic system result, at least in part, from the accumulation of inflammatory cells around lymphatic vessels, leading to impaired lymphatic collecting vessel pumping capacity, leaky initial and collecting lymphatics, alterations in lymphatic endothelial cell (LEC) gene expression, and degradation of junctional proteins.

In the course of obesity, decreased lymphatic vessel density, decreased lymphatic endothelial cell (LEC) proliferation, increased lymphatic permeability, and reduced lymphatic contractility are observed. Although obesity is a major clinical risk factor for lymphedema, the mechanisms that regulate this effect remain incompletely understood. Recent reports have demonstrated that obesity is associated with acquired lymphatic dysfunction.

The relationship appears bidirectional: obesity-induced lymphatic dysfunction can intensify the pathological effects of obesity in other organ systems by regulating leukocyte infiltration and expression of inflammatory cytokines; therefore, obesity-related lymphatic dysfunction worsens the pathological changes associated with obesity.

The defective lymphatic vasculature may disrupt local and systemic immune-metabolic homeostasis, contributing to various adverse outcomes including inflammation and immune dysfunction, abnormal transport dynamics of lipids, vitamin D, and possibly incretin in obesity.

4.3 Inflammation and Cytokines

Adipose tissue expansion may be a critical factor contributing to lymphatic dysfunction in obesity, as the lymphatic vasculature is likely exposed to the influence of a range of metabolites, hormones, and cytokines secreted by the adipose tissue, particularly through paracrine mechanisms. Excess mechanical pressure, metabolites, pro-inflammatory cytokines, and adipokines released during adipose tissue expansion can predispose lymphocytes to overactivation and apoptosis, compromising collecting lymphatic vessels and triggering lymph node hypoplasia, fibrosis, and apoptosis.

4.4 Metabolic Disorders

Defects in the lymphatic system have been associated with metabolic disorders, including metabolic syndrome, obesity, diabetes, and atherosclerosis in animal models. The lymphatic system's role in dietary lipid trafficking, reverse cholesterol transport, and immune regulation positions it as a functional participant in metabolic homeostasis, not merely a passive drainage system.

4.5 Aging and Neurological Associations

Dysfunction in either the meningeal lymphatic or glymphatic pathway has been linked to various CNS diseases such as Alzheimer's disease, Parkinson's disease, and multiple sclerosis. Dysfunction in meningeal lymphatic vessels exacerbates the pathological trajectory of age-related neurodegenerative disease. Sleep and arterial pulsatility critically regulate glymphatic efficiency, offering non-pharmacological therapeutic avenues.

5. Nutrients, Herbs, and Natural Ingredients

5.1 Flavonoids: Diosmin and Hesperidin

Traditional Use

Diosmin is a naturally occurring flavonoid glycoside found in citrus fruits, belonging to the flavone subclass. Diosmin is a flavonoid commonly found in citrus fruits, largely used as adjuvant treatment for circulatory disorders, including chronic venous insufficiency (CVI) and hemorrhoids. Its traditional use in European phytomedicine derives from citrus peel preparations employed to support vascular tone. The most popular plant-origin medicines in pharmacological treatment of CVI include horse chestnut seed extract or aescin isolated from it, and flavonoids: diosmin, hesperidin, rutin, and its derivative troxerutin.

Scientific Evidence

Diosmin has been recognized for its vascular protective properties, particularly in the management of conditions such as lymphedema, varicose veins, and chronic venous insufficiency. Its primary commercial form is a micronized purified flavonoid fraction (MPFF) composed predominantly of diosmin together with hesperidin.

Flavonoids are oral venoactive drugs frequently prescribed to relieve the symptoms of chronic venous disorders. Among venoactive drugs, diosmin is a naturally occurring flavonoid glycoside that can be isolated from various plant sources; it can also be obtained after conversion of hesperidin extracted from citrus rinds. Micronized purified flavonoid fraction (MPFF) is a preparation that contains mainly diosmin and a small fraction of hesperidin.

Three clinical studies met the criteria for a literature review comparing diosmin 600 mg/day and MPFF 1000 mg/day. These clinical studies showed a significant decrease of CVD symptom intensity (up to approximately 50%) and global patient satisfaction after one-to-six-month treatment.

Following oral administration, diosmin is not directly absorbed but must first be hydrolyzed into its aglycone, diosmetin, which is then absorbed into the systemic circulation. This pharmacokinetic step is relevant to bioavailability comparisons between different formulations.

Evidence strength: Anti-inflammatory foods and their effects on the inflammatory state and on oxidative stress are now being investigated for their possible therapeutic role in lymphedema. Although no special diet has so far been proven to be very effective, specific dietary tips could help in alleviating the edematous state of patients with lymphedema. The evidence for diosmin/MPFF in chronic venous insufficiency is moderate (multiple RCTs), but evidence specific to primary lymphedema management is weaker and the condition should be distinguished from venous edema.

5.2 Horse Chestnut Seed Extract (Aesculus hippocastanum, HCSE)

Traditional Use

Horse chestnut (Aesculus hippocastanum) has a long history in European traditional medicine for complaints related to venous insufficiency, heavy legs, and swelling. Seed extracts standardized to the active triterpene saponin, escin (also written aescin), have been used orally in Germany and wider Europe since at least the mid-twentieth century and were assessed under the German Commission E framework.

Scientific Evidence

The extract from horse chestnut seeds, standardized for the content of aescin, is used as the treatment for chronic venous insufficiency. It has anti-inflammatory and anti-oedematous properties and indicates a positive effect on venous tone, rheological properties, and blood coagulability. The mechanism of horse chestnut seed extract/aescin activity was proposed on the basis of in vitro and in vivo studies, and its effectiveness was documented with numerous randomised clinical trials. The results have proven that horse chestnut seed extract not only significantly improves subjective symptoms in patients with chronic venous insufficiency such as calf spasm, leg pain, pruritus, and fatigue, but also reduces leg volume, ankle and calf circumference.

In all trials the extract was standardised to escin. Overall, the trials suggested an improvement in the symptoms of leg pain, oedema and pruritus with horse chestnut seed extract when taken as capsules over two to 16 weeks. The evidence presented suggests that HCSE is an efficacious and safe short-term treatment for CVI. However, several caveats exist and larger, definitive RCTs are required to confirm the efficacy of this treatment option.

Limitation critical to lymphatic health context: Horse chestnut's aescin appears to reduce the permeability of capillary walls, which means less fluid leaks out of blood vessels into surrounding tissues. This can decrease edema in conditions like chronic venous insufficiency, where the problem is venous blood pooling, not lymphatic obstruction. The compound may also have mild anti-inflammatory effects on vessel walls. However, lymph vessels and blood vessels are structurally different, and there is limited evidence that strengthening venous walls directly improves lymphatic function. The evidence for such agents is mixed and often conflates different types of swelling. Most studies focus on chronic venous insufficiency or mild edema, not clinically diagnosed lymphedema.

5.3 Selenium

Traditional / Historical Context

Selenium is an essential trace element required for synthesis of selenoproteins, including glutathione peroxidases. Its relevance to lymphedema emerged from observations of oxidative stress and immune dysregulation in affected tissues. Selenium supplementation for lymphedema has been most studied in post-cancer-treatment populations in Germany and Eastern Europe.

Scientific Evidence

A randomized, double-blind, controlled trial assessed how sodium selenite supplementation would affect breast cancer-related lymphedema (BCRL) symptoms. The trial was conducted on 26 participants with clinical stage II to III BCRL. The control group and selenium group underwent five sessions of 0.9% saline and 500 μg sodium selenite (Selenase®) IV injections, respectively, within 2 weeks.

Compared to baseline, at 2 weeks, 75.0% of participants in the selenium group showed clinical stage improvement, while there was no change in the control group. At follow-up, 83.3% of the selenium group showed stage changes from III to II compared to 10.0% of controls. Extracellular water ratios were significantly reduced at 2 weeks and follow-up, only in the selenium group.

Sodium selenite improved diagnostic stages of BCRL along with extracellular water ratios, although the beneficial effect might not be related to its antioxidant activity. Selenite's effect on lymphedema may be associated with non-antioxidant properties, such as anti-inflammation and immune function. Further mechanistic research using a larger population is needed.

Evidence strength: The selenium RCT described above is small (n=26) and used intravenous administration — limiting direct extrapolation to oral dietary intake. Evidence suggests that specific dietary approaches, along with supplements like selenium, can reduce edema, improve lymphatic function, and modulate inflammation. However, the overall body of evidence remains preliminary and larger trials are warranted.

5.4 Hydroxytyrosol and Polyphenol Combinations

Scientific Evidence

A few supplements have been tested for lymphedema treatment. Among them, GARLIVE® containing hydroxytyrosol, hesperidin, spermidine, and vitamin A exhibited promising effects in the animal model. These findings are preclinical and cannot yet be extrapolated to human recommendations; controlled human trials have not been published to date for this combination.

5.5 Butcher's Broom (Ruscus aculeatus)

Traditional Use

Butcher's broom (Ruscus aculeatus) has been used in European traditional medicine for complaints related to circulatory stagnation in the lower limbs, including heaviness, swelling, and varicose conditions. Active constituents are steroidal saponins called ruscogenins. It is listed in the European Pharmacopoeia and has been assessed under various European regulatory frameworks.

Scientific Evidence

Butcher's broom works with ruscogenins acting as venotonic agents. They may cause mild constriction of veins, improving blood return from the legs. This addresses venous circulation more than lymphatic drainage. The distinction matters because lymphedema and venous edema have different underlying causes and require different treatments. Butcher's broom has been studied mostly in combination products alongside hesperidin and vitamin C, making it difficult to attribute effects to any single ingredient.

Evidence strength: Evidence for ruscogenins and vascular tone is modest and largely mechanistic or in small clinical studies. No high-quality trials have demonstrated clinically significant improvement in lymphedema specifically.

5.6 Rutin and Hydroxyethylrutosides (Oxerutins)

Traditional Use

Rutin is a bioflavonoid (quercetin glycoside) found widely in buckwheat, citrus peel, and elderflower. Hydroxyethylrutosides (oxerutins) are semi-synthetic derivatives of rutin. Both have been used in European phytomedicine as venoactive and anti-oedematous agents. The German Commission E has approved oxerutins for chronic venous insufficiency.

Scientific Evidence

In the 2018 Guidelines According to Scientific Evidence, updated by Nicolaides and coworkers, only five venoactive specialties were considered: MPFF, Ruscus extract plus hesperidin methyl chalcone and ascorbic acid, hydroxyethyl-rutosides, horse chestnut seed extract, and calcium dobesilate. Hydroxyethylrutosides have been evaluated in RCTs for both CVI and post-mastectomy lymphedema. A systematic review by Wadworth and Faulds noted pharmacological plausibility but called for larger, more rigorous trials. Evidence remains moderate for CVI and limited specifically for lymphedema.

5.7 Ketone Bodies and Ketogenic Dietary Patterns

Scientific Evidence (Emerging / Preclinical)

Evidence suggests that specific dietary approaches, such as hypocaloric and ketogenic diets, along with supplements like selenium and hydroxytyrosol, can reduce edema, improve lymphatic function, and modulate inflammation. An animal study published in Nature Metabolism (2019) by García-Caballero et al. examined the role of dietary ketone bodies in lymphatic vessel growth, finding preliminary evidence for lymphangiogenic support. These strategies show promise as adjuncts to traditional treatments, although further clinical research is necessary to confirm their effectiveness. At present, ketogenic diet approaches for lymphatic support are at an early evidence stage, primarily from in vitro and rodent data.

6. Dietary and Lifestyle Factors

6.1 Caloric Balance and Weight Management

It is believed that perilymphatic inflammation induced by obesity may play a significant role in obesity-induced lymphatic dysfunction and that weight loss may reverse this occurrence. Weight loss through diet restriction can reverse several obesity-induced lymphatic dysfunctions, suggesting that the pathological changes in the obese lymphatic system can be reversed and metabolic changes can be restored. Weight reduction is the definitive management to restore lymphatic function and should be instituted before permanent vasculature impairment develops.

6.2 Dietary Fat Composition and Intestinal Lymphatics

The intestinal lymphatic system is physiologically engaged every time dietary fat is consumed. Administration of lipids increases the flux of lymphocytes from the intestinal mucosa to the mesenteric lymph node through the intestinal lymph. The contraction frequency of intestinal collecting lymphatics was also enhanced by olive oil administration. This points to a direct, near-immediate coupling between fat intake and lymphatic activity.

Considerable efforts have been directed at defining the influence of nutrition on the immune system. There is considerable evidence implicating dietary fat as a modulator of different immune functions.

6.3 Anti-Inflammatory Dietary Patterns

Nutrition and nutritional status are extremely important in lymphedema physiopathology. Obesity is a comorbidity that exacerbates the risk for secondary lymphedema and constitutes a negative prognostic factor. Anti-inflammatory foods and their effects on the inflammatory state and on oxidative stress are now being investigated for their possible therapeutic role in lymphedema.

6.4 Sodium Intake

Sodium restriction is a commonly discussed dietary recommendation in edema management. While the physiological rationale is sound (sodium promotes fluid retention), direct clinical evidence in lymphedema specifically is sparse. Expert clinical guidance, such as that synthesized from practitioners in the field, has generally suggested limiting sodium to under 2,300 mg per day and watching for hidden salt in condiments and packaged items, though this recommendation is based primarily on extrapolation from fluid regulation physiology rather than large lymphedema-specific trials.

6.5 Exercise and Physical Activity

Physical movement is one of the most evidence-supported lifestyle influences on lymphatic function. Recent studies have suggested that exercise can improve peripheral lymphatic function. Exercise enhances the frequency and vigor of lymphatic pumping and decreases lymphatic vessel leakiness, indicating a reversal in the pathology of the lymphatic endothelium.

Extrinsic forces such as skeletal muscle contraction promote lymphatic flow and improve blood circulation together with lymphatic circulation. In cancer survivors specifically, exercise improves lymph flow and protein resorption in breast cancer survivors with lymphedema and mitigates lymphedema and its symptomatology.

Lymphedema is incurable and treated with physical therapy, such as complex decongestive therapy (CDT), which is currently considered the most successful intervention. The treatment consists of manual lymphatic drainage, compression therapy, exercise, and skin care.

6.6 Sleep and Circadian Regulation (Glymphatic Context)

Research on the glymphatic system has elevated sleep as a relevant lifestyle factor for central lymphatic function. Sleep and arterial pulsatility critically regulate glymphatic efficiency, offering non-pharmacological therapeutic avenues. The clinical translation of these findings to dietary and lifestyle guidance remains an active research area, with current evidence primarily from animal models, though the mechanistic rationale is supported by neuroimaging studies in humans.

6.7 Protein Intake

A commonly held but evidence-limited belief is that protein should be restricted in lymphedema because lymph fluid is protein-rich. Despite the fact that lymphedema fluid contains protein, current standard of care is to NOT restrict protein. Adequate protein intake is considered important for maintaining tissue integrity and supporting immune competence, which are both relevant to lymphatic health.

6.8 Hydration

Adequate hydration is discussed in clinical lymphedema management contexts. While there are no large RCTs evaluating hydration as an isolated variable in lymphedema, the physiological rationale is that adequate hydration supports the overall fluid equilibrium within which the lymphatic system operates. Clinical guidance from practitioners typically recommends adequate daily water intake as part of a holistic approach to edema management, though this should be understood as expert opinion rather than high-quality trial evidence.

7. Summary of Evidence Levels

• Obesity/weight management and lymphatic function: Multiple controlled animal studies and observational human data; weight loss shown to reverse some lymphatic dysfunction. Strength: moderate-to-good for animal models; moderate for human observational evidence.
• Exercise and lymphatic pumping: Multiple clinical and mechanistic studies; endorsed within complex decongestive therapy protocols. Strength: moderate-to-good.
• Diosmin/MPFF for venous/lymphatic edema: Multiple RCTs in CVI; fewer specifically in lymphedema. Strength: moderate for CVI; low-to-moderate for lymphedema.
• Horse chestnut seed extract (aescin) for CVI: Cochrane review found short-term efficacy for CVI; no high-quality evidence specifically for lymphedema. Strength: moderate for CVI; insufficient for lymphedema.
• Selenium (intravenous sodium selenite) for BCRL: One small RCT (n=26); promising but inconclusive. Strength: preliminary.
• Ketogenic/hypocaloric diets: Animal models and a limited number of human studies; emerging area. Strength: preliminary.
• Hydroxytyrosol combinations: Animal models only. Strength: preclinical only.
• Butcher's broom / ruscogenins: Mechanistic plausibility; limited human trials; mostly in combination products for CVI. Strength: low-to-moderate for CVI; insufficient for lymphedema.
• Glymphatic/meningeal lymphatic system and sleep, aging: Strong mechanistic evidence in animal models; growing neuroimaging evidence in humans; therapeutic translation still emerging. Strength: emerging/moderate.

References

• Alitalo K. The lymphatic vasculature in disease. Nature Medicine, 2011 — The lymphatic system in health and disease (PubMed)
• Null M, Arbor TC, Agarwal M. Anatomy, Lymphatic System. StatPearls [Internet]. NIH/NCBI Bookshelf, 2023
• Definition, Epidemiology and Pathophysiology of Lymphoedema. PMC / Cells, 2025
• Epidemiological Study of Lymphedema Prevalence and Comorbidities in Hospitalized Patients in the United States. PMC, 2025
• Lymphedema — StatPearls. NIH/NCBI Bookshelf, 2025
• Regulation of Lymphatic Function in Obesity. PMC / Frontiers in Physiology, 2020
• The lymphatic vasculature: its role in adipose metabolism and obesity. PMC, 2017
• Adipose Tissue and Biological Factors — Possible Link between Lymphatic System Dysfunction and Obesity. PMC, 2021
• Obesity increases inflammation and impairs lymphatic function in a mouse model of lymphedema. PMC / American Journal of Physiology, 2014
• To be or not to be obese: impact of obesity on lymphatic function. PMC, 2017
• Obesity Impairs Lymphatic Fluid Transport and Dendritic Cell Migration to Lymph Nodes. PMC, 2013
• The role of lymphatics in intestinal inflammation. PMC, 2021
• Lymphatic transport of high-density lipoproteins and chylomicrons. PMC, 2014
• Lewis GF. Emerging Role of Lymphatics in the Regulation of Intestinal Lipid Mobilization. Frontiers in Physiology, 2019
• Editorial: Lymphatic system — organ specific functions in health and disease. PMC / Frontiers, 2023
• Editorial: Lymphatic system — organ specific functions in health and disease, volume II. PMC, 2025
• Defective lymphatic vasculature in obesity. PMC, 2025
• A Lymphatic Perspective on Obesity and Inflammatory Arthritis. PMC, 2025
• Exercise-Induced Cardiac Lymphatic Remodeling Mitigates Inflammation in the Aging Heart. PMC, 2025
• Exercise training improves obesity-related lymphatic dysfunction. PMC, 2016
• The effects of postoperative treadmill exercise on rats with secondary lymphedema. PMC, 2023
• Is There a Difference in the Clinical Efficacy of Diosmin and Micronized Purified Flavonoid Fraction for the Treatment of Chronic Venous Disorders? PMC, 2021
• Diosmin: A promising phytochemical for functional foods, nutraceuticals and cancer therapy. PMC, 2024
• Comparative Bioavailability of Two Diosmin Formulations after Oral Administration to Healthy Volunteers. PMC, 2018
• Cochrane Summary of Findings: Horse Chestnut Seed Extract for Chronic Venous Insufficiency. PMC, 2013
• Pittler MH, Ernst E. Horse chestnut seed extract for chronic venous insufficiency. Cochrane Database of Systematic Reviews, 2012
• Horse chestnut — efficacy and safety in chronic venous insufficiency: an overview. ScienceDirect, 2015
• Dietary supplements in lymphedema. PMC / Journal of Preventive Medicine and Hygiene, 2022
• Sodium Selenite Alleviates Breast Cancer-Related Lymphedema Independent of Antioxidant Defense System. PMC, 2019
• Fueling lymphatic health: the emerging role of nutrition in lymphedema management. Veins and Lymphatics, 2025
• Role of the Glymphatic System in Alzheimer's Disease and Treatment Approaches: A Narrative Review. PMC, 2024
• Glymphatic and meningeal lymphatic dysfunction in Alzheimer's disease: Mechanisms and therapeutic perspectives. PMC, 2025
• Functional aspects of the brain lymphatic drainage system in aging and neurodegenerative diseases. PMC, 2024
• Involvement of the glymphatic/meningeal lymphatic system in Alzheimer's disease: insights into proteostasis. PMC, 2024
• Functional classification of secondary lymphedema. PMC, 2019